TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Hold” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $63.00.

Several brokerages recently issued reports on TGTX. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Jefferies Financial Group restated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. Bank of America boosted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright restated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a report on Tuesday.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Danske Bank A S purchased a new stake in TG Therapeutics in the 3rd quarter valued at approximately $25,000. EverSource Wealth Advisors LLC increased its position in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares in the last quarter. Hantz Financial Services Inc. increased its position in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 560 shares in the last quarter. Truvestments Capital LLC raised its holdings in shares of TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of TG Therapeutics in the fourth quarter worth $52,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Trading Up 3.3%

Shares of TG Therapeutics stock opened at $56.09 on Wednesday. The company has a 50-day moving average of $53.41 and a two-hundred day moving average of $42.28. TG Therapeutics has a 12-month low of $26.76 and a 12-month high of $59.30. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The stock has a market cap of $8.59 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 2.33 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million for the quarter, compared to analysts’ expectations of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.TG Therapeutics’s revenue was up 70.2% compared to the same quarter last year. During the same period last year, the firm earned $0.17 EPS. On average, research analysts anticipate that TG Therapeutics will post 0.92 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.